Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Mitsuo Hori"'
Autor:
Jiro Kikuchi, Mitsuo Hori, Naoki Osada, Sae Matsuoka, Atsushi Suzuki, Satoshi Kakugawa, Hiroshi Yasui, Takeshi Harada, Hirofumi Tenshin, Masahiro Abe, Hideki Nakasone, Yusuke Furukawa
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/e14a95c44b6d4444a7baef0a978500e9
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7156 (2024)
Diffuse Large B-cell Lymphoma (DLBCL), with its intrinsic genetic and epigenetic heterogeneity, exhibits significantly variable clinical outcomes among patients treated with the current standard regimen. Disulfidptosis, a novel form of regulatory cel
Externí odkaz:
https://doaj.org/article/ae588a53be3d42c794cf44770f9d0618
Autor:
Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, Naoki Hijiya, Masatsugu Moriyama, Shotaro Hagiwara, Shuichi Kusano, Masumichi Saito, Kamruddin Ahmed, Akira Nishizono, Hiroshi Handa, Kazuhiro Morishita
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has
Externí odkaz:
https://doaj.org/article/c652ad6387c14272840172d06da6e59c
Autor:
Satoko Nakano, Emi Ikebe, Yoshiyuki Tsukamoto, Yan Wang, Takashi Matsumoto, Takahiro Mitsui, Takaaki Yahiro, Kunimitsu Inoue, Hiroaki Kawazato, Aiko Yasuda, Kanako Ito, Shigeo Yokoyama, Naohiko Takahashi, Mitsuo Hori, Tatsuo Shimada, Masatsugu Moriyama, Toshiaki Kubota, Katsushige Ono, Wataru Fujibuchi, Kuan-Teh Jeang, Hidekatsu Iha, Akira Nishizono
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73205 (2013)
Tax1-binding protein 1 (Tax1bp1) negatively regulates NF-κB by editing the ubiquitylation of target molecules by its catalytic partner A20. Genetically engineered TAX1BP1-deficient (KO) mice develop age-dependent inflammatory constitutions in multip
Externí odkaz:
https://doaj.org/article/2db2cf33f8c34d35a7cd341ca6838de5
Autor:
Meletios A. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, David Yao, Prianka Das, Jesús San-Miguel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132 ), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patient
Autor:
Suresh Shelat, Kohmei Kubo, Morio Matsumoto, Chiaki Nakaseko, Mitsuo Hori, Shotaro Hagiwara, Kenshi Suzuki, Shigeki Ito, Kiyohiko Hatake, Masafumi Miyoshi, Gen Kinoshita, Hiroshi Handa, Naoki Takezako, Kensuke Ohta, Kazuteru Ohashi
Publikováno v:
International Journal of Hematology. 111:65-74
Novel therapies are needed for patients with newly diagnosed multiple myeloma (NDMM). Elotuzumab plus lenalidomide and dexamethasone (ELd) is approved for the treatment of relapsed/refractory multiple myeloma (RRMM). This phase 2 study in Japan evalu
Autor:
Masafumi Miyoshi, Satoshi Kakugawa, Mitsuo Hori, Yusuke Furukawa, Kenshi Suzuki, Atsushi Suzuki, Kensuke Ohta
Publikováno v:
Leukemia. 34:3088-3090
Autor:
Hidekatsu Iha, Noriko Toyama-Sorimachi, Daisuke Koyama, Atsushi Suzuki, Yoshiaki Kuroda, Shotaro Hagiwara, Mitsuo Hori, Yusuke Furukawa, Jiro Kikuchi, Tohru Izumi, Hiroshi Yasui
Publikováno v:
Leukemia. 34:180-195
SLAMF7 is expressed mainly on multiple myeloma (MM) cells and considered an ideal target for immunotherapeutic approaches. Indeed, elotuzumab, an anti-SLAMF7 antibody, is used for the treatment of MM in combination with immunomodulatory drugs. SLAMF7
Autor:
Junichi Mukae, Takuya Komeno, Noriko Doki, Keisuke Tanaka, Atsushi Shinagawa, Takeshi Kobayashi, Kazuteru Ohashi, Takashi Kumagai, Megumi Akiyama, Naoki Wakimoto, Hiroshi Kojima, Daisuke Kudo, Shigeo Toyota, Yuichi Nakamura, Koh Yamamoto, Kazuhiko Kakihana, Tatsuya Saito, Hina Takano, Mitsuo Hori, Yuho Najima, Chikashi Yoshida, Masahide Yamamoto, Ikuyo Tsutsumi, Yasushi Okoshi, Takayuki Fujio, Aiko Igarashi
Publikováno v:
Acta Haematologica. 141:111-118
We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of fo
Autor:
Mitsuo Hori, Naoki Takezako, Meletios A. Dimopoulos, Suresh Shelat, Philippe Moreau, Marc S. Raab, Mihaela Popa McKiver, Paul G. Richardson, Jesús F. San-Miguel, Michael Robbins, Ying Ming Jou, Dominik Dytfeld, Kenshi Suzuki, Richard Leblanc, Sebastian Grosicki, Xavier Leleu, Brian Rafferty
Publikováno v:
New England Journal of Medicine. 379:1811-1822
The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been show